Aug 5, 2026 07:00AM
May 7, 2026 07:10AM
May 7, 2026 07:00AM
May 7, 2026 07:00AM
Feb 26, 2026 07:00AM
Feb 17, 2026 07:00AM
Jan 8, 2026 07:05AM Entrada Therapeutics advances DMD trials, expands to ocular diseases
Jan 8, 2026 07:00AM
Dec 19, 2025 09:06AM
Mar 25, 2025 06:51AM
Mar 24, 2025 01:50PM
Mar 24, 2025 09:15AM
Mar 24, 2025 07:01AM
Mar 24, 2025 07:00AM Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular
Feb 28, 2025 12:43AM
Feb 27, 2025 07:00AM
Feb 25, 2025 06:49AM
Feb 24, 2025 07:00AM
Feb 24, 2025 07:00AM
Mar 13, 2024 07:00AM
Nov 22, 2023 07:23AM Entrada Therapeutics (TRDA) Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
Nov 22, 2023 07:00AM
Nov 7, 2023 07:00AM
Aug 8, 2023 07:00AM
May 10, 2023 07:00AM
Mar 23, 2023 10:19AM
Mar 6, 2023 07:00AM
Mar 6, 2023 07:00AM Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Dec 19, 2022 05:38PM
Dec 19, 2022 04:30PM
Dec 19, 2022 04:30PM
Dec 19, 2022 04:30PM
Nov 7, 2022 07:00AM
Nov 7, 2022 07:00AM
Aug 11, 2022 07:00AM Entrada Therapeutics Reports Second Quarter 2022 Financial Results
Aug 11, 2022 07:00AM
Aug 4, 2022 07:05AM
Aug 4, 2022 07:00AM
Aug 4, 2022 07:00AM
May 12, 2022 07:03AM
May 12, 2022 07:00AM
May 12, 2022 07:00AM Entrada Therapeutics Reports First Quarter 2022 Financial Results
May 11, 2022 09:32AM
May 11, 2022 09:30AM
May 11, 2022 09:30AM

328,350 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All